BioAsia’s Genome Valley Excellence Award 2026 to Honour Bruce Levine
Table of Contents
Relevance:
TGPSC GR I Paper–V: Science & Technology
For Prelims:
- Bio Asia, Genome Valley Excellence Award, CAR T-Cell Therapy, Cell and Gene Therapy, Cancer Immunotherapy
For Mains:
- Precision Medicine, Translational Biomedical Research, TechBio Convergence (AI + Biology), Biotechnology Innovation Ecosystem, Living Medicines & Gene Editing
Why in News?
The Genome Valley Excellence Award 2026, a prestigious recognition presented at the annual BioAsia Life Sciences Conference in Hyderabad, will be conferred on Dr. Bruce Levine for his groundbreaking contributions to cell and gene therapy and cancer immunotherapy.
Awardee and Contribution
Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania’s Perelman School of Medicine, has been selected for his pioneering work in:
- Cell and Gene Therapy
- Engineered T-Cell Therapies
- CAR T-Cell Immunotherapy
- Personalised Living Medicines
His research has enabled the safe genetic modification of human cells, forming the scientific basis for next-generation personalised treatments.
Through landmark discoveries and clinical trials, Dr. Levine played a critical role in the development of CAR T-cell therapies, which contributed to the emergence of the first FDA-approved gene therapies for cancer.
These innovations have transformed treatment approaches for previously incurable cancers and strengthened global standards in translational biomedical research.
Gene Therapy
What is Gene Therapy?
- Gene therapy is a medical technique that alters or modifies genes to treat or prevent diseases.
- It works by changing gene expression or modifying the biological properties of living cells for therapeutic purposes.
- It is used in the treatment of cancer, genetic disorders, and infectious diseases.
Mechanisms of Gene Therapy
Gene therapy can function through multiple approaches:
- Gene Replacement – Substituting a defective gene with a healthy copy.
- Gene Inactivation – Silencing or disabling a harmful or malfunctioning gene.
- Gene Addition/Modification – Introducing a new or modified gene to help fight disease.
Types of Gene Therapy Products
- Plasmid DNA
- Circular DNA molecules engineered to carry therapeutic genes into cells.
- Viral Vectors
- Modified viruses (rendered non-infectious) used as delivery vehicles to transfer genes into human cells.
- Bacterial Vectors
- Genetically modified bacteria used to transport therapeutic genes into tissues.
- Gene Editing Technologies
- Techniques aimed at repairing mutated genes or disrupting harmful genes.
- Patient-Derived Cellular Gene Therapy
- Patient’s cells are removed, genetically altered (often using viral vectors), and reintroduced into the body.
Types Based on Delivery Method
- Ex Vivo Gene Therapy
- Cells are modified outside the body and then transplanted back into the patient.
- In Vivo Gene Therapy
- Genetic modification occurs directly inside the patient’s body.
BioAsia 2026: Theme and Focus
The two-day BioAsia 2026 conference, beginning February 17 in Hyderabad, will be held under the theme:
“TechBio Unleashed: AI, Automation and the Biology Revolution.”
The conference will explore:
- Convergence of Artificial Intelligence (AI) and advanced biology
- Intelligent manufacturing in life sciences
- Transformation in drug discovery and therapy development
- Future of precision and personalised medicine
Significance
- Reinforces Hyderabad’s position as a global life sciences hub under Genome Valley.
- Highlights India’s growing role in biotechnology, immunotherapy, and translational research.
- Demonstrates the integration of AI, automation, and biotech innovation in modern healthcare.
The award underscores Telangana’s commitment to recognising global scientific excellence while strengthening its standing in the global biotechnology ecosystem.
CARE MCQ
Q. With reference to recent developments in ‘Recombinant Vector Vaccines’, consider the following statements:
- Genetic engineering techniques are employed in the development of these vaccines.
- Both bacteria and viruses can be used as vectors in such vaccines.
Which of the statements given above is/are correct?
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
Answer: C
Explanation:
- Statement 1 is correct: Recombinant vector vaccines rely on genetic engineering. Scientists isolate a gene encoding a specific antigen from a pathogen and insert it into the genetic material of a harmless carrier organism (vector). This engineered vector then produces the antigen inside the host body, triggering an immune response without causing the actual disease.
- Statement 2 is correct: Both viruses and bacteria can serve as vectors. Viral vectors (such as adenoviruses) are widely used, but certain attenuated bacterial strains (e.g., Salmonella or Listeria) can also be genetically modified to deliver antigenic material. These vectors simulate natural infection pathways, thereby generating strong and effective immunity.
